2024
12241 Association Between Brain Glucose And Circulating Glucagon Levels In Response To Acute Hyperglycemia
Matson B, Gunawan F, Coppoli A, Jiang L, Rangel E, De Aguiar R, Rothman D, Mason G, Hwang J. 12241 Association Between Brain Glucose And Circulating Glucagon Levels In Response To Acute Hyperglycemia. Journal Of The Endocrine Society 2024, 8: bvae163.674. PMCID: PMC11454728, DOI: 10.1210/jendso/bvae163.674.Peer-Reviewed Original ResearchCentral nervous systemBrain glucose levelsPlasma glucagon levelsHyperglycemic clampType 2 diabetesGlucagon levelsGlucagon secretionGlucose levelsResponse to hyperglycemiaAcute hyperglycemiaOral glucose tolerance testBrain glucose metabolismResponse to central nervous systemPathophysiology of type 2 diabetesResponse to hypoglycemiaBrain glucoseIndices of insulin sensitivityEffect of obesityRegulation of glucagon secretionGlucose tolerance testConsequences of obesityModulating glucagon secretionOvert metabolic abnormalitiesBrain glucose uptakeCirculating glucagon levels
2023
Liver Transplantation in a Woman with Mahvash Disease
Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri V, Miller J, Maley W, Shah A, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler D. Liver Transplantation in a Woman with Mahvash Disease. New England Journal Of Medicine 2023, 389: 1972-1978. PMID: 37991855, DOI: 10.1056/nejmoa2303226.Peer-Reviewed Original ResearchConceptsPortal hypertensionLiver transplantationPancreatic hypertrophyMahvash diseasePancreatic α cell hyperplasiaAbsence of cirrhosisNoncirrhotic portal hypertensionΑ-cell hyperplasiaRare genetic disorderSerum glucagonDefinitive treatmentGlucagon levelsVascular diseaseMedical CenterHypertensionDiseaseAmmonia levelsHyperglucagonemiaGenetic disordersTransplantationHypertrophyGlucagonWomenHematemesisCirrhosisWeight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M, Nian H, Mayfield D, Devin J, Gamboa J, Yu C, Silver H, Niswender K, Luther J, Brown N. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes 2023, 73: 38-50. PMID: 37874653, PMCID: PMC10784656, DOI: 10.2337/db23-0356.Peer-Reviewed Original ResearchConceptsEndogenous GLP-1Glucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsImproved insulin sensitivityInsulin sensitivityGLP-1GLP-1RGlucagon levelsGlucose levelsMatsuda indexWeight lossHypocaloric dietPostprandial glucoseInhibitor sitagliptinReceptor agonistMetabolic effectsDiet-induced weight lossDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent effectsDPP-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionMixed meal testGLP-1R antagonist
2018
Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia
Belfort-DeAguiar R, Gallezot JD, Hwang JJ, Elshafie A, Yeckel CW, Chan O, Carson RE, Ding YS, Sherwin RS. Noradrenergic Activity in the Human Brain: A Mechanism Supporting the Defense Against Hypoglycemia. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 2244-2252. PMID: 29590401, PMCID: PMC6456998, DOI: 10.1210/jc.2017-02717.Peer-Reviewed Original ResearchConceptsHyperinsulinemic-hypoglycemic clampRaphe nucleusCounterregulatory hormonal responsesInsulin-treated patientsOptimal glycemic controlPositron emission tomographic imagingGlucose infusion rateBrain responsesLean healthy volunteersEmission tomographic imagingGlycemic controlNA outputGlucagon levelsPlasma epinephrineNoradrenergic activationNA responseNoradrenergic activityAutonomic outputIntravenous injectionHealthy volunteersInfusion rateHypoglycemiaMotor activityGrowth hormoneHormonal responses
2017
Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi A, Sherr J, VanName M, Carria L, Zgorski M, Tichy E, Weyman K, Cengiz E, Weinzimer S, Tamborlane W. Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1088-1094. PMID: 29211871, PMCID: PMC6276715, DOI: 10.1210/jc.2017-02265.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testPlasma glucagon responseWeeks of treatmentGlucagon responsePostprandial hyperglycemiaMeal-stimulated increaseWeeks of therapyPlasma glucagon levelsType 1 diabetesPlasma glucose curveBolus insulin administrationMixed meal feedingDl/minGlucagon curveAdjunctive treatmentGlucagon levelsPlasma glucagonTolerance testIncremental areaInsulin administrationGlucose curvePostmeal hyperglycemiaLiraglutideGlucose responsePretreatment responsesAltered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study
Patel NS, Van Name MA, Cengiz E, Carria LR, Weinzimer SA, Tamborlane WV, Sherr JL. Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study. Diabetes Technology & Therapeutics 2017, 19: 618-622. PMID: 29068709, PMCID: PMC5689123, DOI: 10.1089/dia.2017.0267.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsPlasma glucoseType 1 diabetesDiabetic ketoacidosisFree fatty acidsCANA treatmentBasal insulinGlucagon levelsMetabolic decompensationPlasma insulinInfusion site problemsCotransporter 2 inhibitorsBaseline plasma glucoseFailure of patientsBasal insulin infusionAdjunctive treatmentRate of ketogenesisSGLT2 inhibitorsT1D patientsT1D participantsInsulin infusionMagnitude of increasePG levelsSuspension studiesΒ-hydroxybutyrate
2016
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range
2015
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
Camporez JP, Asrih M, Zhang D, Kahn M, Samuel VT, Jurczak MJ, Jornayvaz FR. Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21. Journal Of Endocrinology 2015, 226: 207-217. PMID: 26203166, DOI: 10.1530/joe-15-0136.Peer-Reviewed Original ResearchConceptsHepatic insulin resistanceFGF21 KO miceInsulin resistanceHepatic glucose productionKetogenic dietKO miceHepatic glucoseLipid metabolismGlucose productionFibroblast growth factor 21Littermate WT controlsRole of FGF21Growth factor 21Plasma glucagon levelsType 2 diabetesPotential pharmacological agentsFGF21 resistanceGlucagon levelsFactor 21Fat massMale miceWT littermatesPharmacological agentsWT controlsInsulin action
2014
Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice
Kim JD, Toda C, D’Agostino G, Zeiss CJ, DiLeone RJ, Elsworth JD, Kibbey RG, Chan O, Harvey BK, Richie CT, Savolainen M, Myöhänen T, Jeong JK, Diano S. Hypothalamic prolyl endopeptidase (PREP) regulates pancreatic insulin and glucagon secretion in mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2014, 111: 11876-11881. PMID: 25071172, PMCID: PMC4136568, DOI: 10.1073/pnas.1406000111.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood GlucoseGene ExpressionGene Knockdown TechniquesGlucagonGlucose Clamp TechniqueGlucose IntoleranceHypothalamusIndolesInsulinInsulin SecretionIon ChannelsMaleMiceMice, TransgenicMitochondrial ProteinsPancreasPhosphorylationProlyl OligopeptidasesReceptor, InsulinRecombinant ProteinsSerine EndopeptidasesSerine Proteinase InhibitorsThiazolidinesUncoupling Protein 1Ventromedial Hypothalamic NucleusConceptsWild-type miceGlucose intoleranceGlucagon secretionProlyl endopeptidaseHyperinsulinemic-euglycemic clamp studiesWild-type control miceGlucose-induced insulin releaseGlucose-induced insulin secretionEuglycemic clamp studiesAutonomic nervous systemVMH injectionsSympathetic outflowWild-type controlsNorepinephrine levelsGlucagon levelsGlucose toleranceControl miceInsulin levelsCentral infusionPancreatic functionVentromedial nucleusInsulin secretionNeuronal activationGlucose-intolerant phenotypeCentral regulation
2013
Alterations in Glucose Homeostasis in a Murine Model of Chagas Disease
Nagajyothi F, Kuliawat R, Kusminski CM, Machado FS, Desruisseaux MS, Zhao D, Schwartz GJ, Huang H, Albanese C, Lisanti MP, Singh R, Li F, Weiss LM, Factor SM, Pessin JE, Scherer PE, Tanowitz HB. Alterations in Glucose Homeostasis in a Murine Model of Chagas Disease. American Journal Of Pathology 2013, 182: 886-894. PMID: 23321322, PMCID: PMC3586686, DOI: 10.1016/j.ajpath.2012.11.027.Peer-Reviewed Original ResearchConceptsPancreatic β-cellsChagas diseaseΒ-cellsGlucose-6-phosphatase mRNAChronic phaseInsulin levelsCruzi infectionGlucose homeostasisPlasma membraneInsulin granulesΒ-cell dysfunctionTrypanosoma cruziHost glucose homeostasisT. cruzi infectionElevated glucagon levelsΑ-cell functionAdrenergic receptor agonistDiminished insulin responsePancreatic islet architectureReduced insulinMice resultsAcute infectionCardiac dysfunctionGlucagon levelsPancreatic inflammation
2000
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
Oren D, Berman R, Anand A, Charney D. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects. Psychiatry Research 2000, 94: 263-266. PMID: 10889291, DOI: 10.1016/s0165-1781(00)00158-x.Peer-Reviewed Original Research
1996
Time course of the defective α-cell response to hypoglycemia in diabetic BB rats
Jacob R, Dziura J, Morgen J, Shulman G, Sherwin R. Time course of the defective α-cell response to hypoglycemia in diabetic BB rats. Metabolism 1996, 45: 1422-1426. PMID: 8931649, DOI: 10.1016/s0026-0495(96)90125-0.Peer-Reviewed Original ResearchConceptsInsulin-dependent diabetes mellitusDays of diabetesBB ratsBB/Wor ratsNondiabetic BB ratsΑ-cell responseDiabetic BB ratsCourse of diabetesPancreatic glucagon levelsPancreatic glucagon contentBeta-cell functionPancreatic insulin contentHypoglycemic challengeCounterregulatory responsesDiabetes onsetDiabetes mellitusGlucagon levelsGlucagon releasePlasma glucagonGlucagon concentrationsInsulin clampGlucagon contentBaseline plasmaDisease onsetGroup 2
1992
Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism
Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. American Journal Of Physiology 1992, 262: e130-e133. PMID: 1733244, DOI: 10.1152/ajpendo.1992.262.1.e130.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIGF-I levelsGrowth factor IInsulin secretionTotal IGF-I levelsFree IGF-I levelsAcid metabolismRecombinant human insulin-like growth factor IFactor IAmino acid metabolismFree fatty acid metabolismHealthy nonobese subjectsHuman insulin-like growth factor IHepatic glucose productionBranched-chain amino acidsExogenous glucose infusionFatty acid metabolismGlucagon levelsInsulin levelsNonobese subjectsContinuous infusionConcomitant inhibitory effectTwo- to threefold increaseC-peptideGlucose infusion
1986
Removal of infused amino acids by splanchnic and leg tissues in humans
Gelfand RA, Glickman MG, Jacob R, Sherwin RS, DeFronzo RA. Removal of infused amino acids by splanchnic and leg tissues in humans. American Journal Of Physiology 1986, 250: e407-e413. PMID: 3963181, DOI: 10.1152/ajpendo.1986.250.4.e407.Peer-Reviewed Original ResearchConceptsAmino acid infusionInfused amino acidsSplanchnic uptakeBranched-chain amino acidsAcid infusionBlood amino acid concentrationsAmino acid loadLeg tissuesNet splanchnic uptakeAmino acid disposalGlucogenic amino acidsLeg effluxGlucagon levelsPeripheral veinSplanchnic visceraPlasma insulinAmino acid uptakeBody skeletal muscleLeg balanceSplanchnic bedAmino acid concentrationsNormal volunteersAcid disposalSplanchnic tissuesNormal humans
1979
Necrolytic Migratory Erythema Without Glucagonoma: Report of Two Cases
Goodenberger D, Lawley T, Strober W, Wyatt L, Sangree M, Sherwin R, Rosenbaum H, Braverman I, Katz S. Necrolytic Migratory Erythema Without Glucagonoma: Report of Two Cases. JAMA Dermatology 1979, 115: 1429-1432. PMID: 533289, DOI: 10.1001/archderm.1979.04010120027012.Peer-Reviewed Original ResearchThe Influence of Obesity and Diabetes in the Monkey on Insulin and Glucagon Binding to Liver Membranes*
LOCKWOOD D, HAMILTON C, LIVINGSTON J. The Influence of Obesity and Diabetes in the Monkey on Insulin and Glucagon Binding to Liver Membranes*. Endocrinology 1979, 104: 76-81. PMID: 221171, DOI: 10.1210/endo-104-1-76.Peer-Reviewed Original ResearchConceptsGroup of obese animalsObese animalsInsulin resistanceFasting plasma insulin concentrationInsulin bindingInfluence of obesityGlucagon bindingPlasma glucagon levelsHormone resistanceHypothalamic obesityImpairment of insulin bindingCarbohydrate intoleranceSpontaneous obesityHepatic insulin receptorsDiminished insulinPlasma insulin concentrationsHuman obesityNonketotic diabetesSignificant inverse relationshipObesityPrimate modelGlucagon levelsRhesus monkeysPlasma glucagonDiabetes
1978
Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs
Shulman G, Liljenquist J, Williams P, Lacy W, Cherrington A. Glucose Disposal during Insulinopenia in Somatostatin-Treated Dogs. Journal Of Clinical Investigation 1978, 62: 487-491. PMID: 670404, PMCID: PMC371787, DOI: 10.1172/jci109150.Peer-Reviewed Original ResearchConceptsNet hepatic glucose uptakeHepatic glucose productionHepatic glucose uptakeGlucagon secretionHepatic glucose storageBasal insulinGlucagon levelsGlucose storageNet hepatic glucose productionGlucose productionGlucose uptakeAbility of hyperglycemiaPancreatic hormone releasePlasma glucagon concentrationsPlasma glucagon levelsInduction of hyperglycemiaPlasma glucose levelsPlasma glucose concentrationHepatic glucose balanceIntraportal insulinGlucagon concentrationsConscious dogsSomatostatin inhibitionGlucagon infusionGlucose disposal
1975
Glucagon secretion in acute and chronic pancreatitis.
DONOWITZ M, HENDLER R, SPIRO H, BINDER H, FELIG P. Glucagon secretion in acute and chronic pancreatitis. Annals Of Internal Medicine 1975, 83: 778-81. PMID: 1200523, DOI: 10.7326/0003-4819-83-6-778.Peer-Reviewed Original ResearchConceptsAcute pancreatitisPancreatic insufficiencyAlpha-cell responsivenessChronic pancreatic insufficiencyBasal glucagon levelsPancreatic glucagon concentrationsInfusion of alaninePrevious pancreatitisGlucagon responseAcute episodeGlucagon levelsGlucagon secretionChronic pancreatitisPlasma glucagonGlucagon concentrationsInitial episodeHealthy controlsPancreatitisCell responsivenessPatientsBasal statePrevious attacksSensitive indexInitial attackInsufficiency
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply